



PATENT APPLICATION: A-64260-2/RMS/AMS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE N

Examiner: Tahira H. Bhatti

Group Art Unit: 1627

Serial No.: 08/963,368

In re application of:

Garry P. Nolan

Filed: November 3, 1997

For: METHODS FOR SCREENING
FOR TRANSDOMINANT
INTRACELLULAR EFFECTOR
PEPTIDES AND RNA

**MOLECULES** 

Certificate of Mailing

1 hereby certify that this correspondence, including listed enclosures, is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to:
Assistant Commissioner for Patents, Office of Initial Patent Examination. Customer Service Center. Washington, DC 202310n: \_\_\_May 2, 2002\_

igned: 🔟

Lica leabetta

### SECOND REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231

Sir:

Appended hereto is a copy of the Official Filing Receipt for the above-identified patent application with the errors indicated in red.

Please note that this is our <u>second</u> request for this same set of errors.

Serial No.:

08/963,368

Filed:

November 3, 1997

In the Address portion of the filing receipt, before "HOHBACH", delete "FLENR" and insert – FLEHR –.

In the Applicant(s) portion of the filing receipt, before "P. NOLAN", please delete "GERRY" and insert – GARRY–.

In the Continuing Data as Claimed by Applicant portion of the filing receipt, after "08/789,333 01/23/1997 PAT 6,153,380", please delete all – and insert the following: and a con of 08/787,738 01/23/97,

which are both CIPs of 08/589,109 01/23/96,

and 08/589,911 01/23/96

In the Title portion of the filing receipt, after "SCREENING FOR" and before "INTRACELLULAR", please delete "TRANSDOMINAT" and insert – TRANSDOMINANT –.

In this same portion of the filing receipt, after "EFFECTOR" and before "AND RNA MOLECULES", please delete "PEPIDES" and insert – PEPTIDES –.

Serial No.:

08/963,368

Filed:

November 3, 1997

The Title will then properly read as follows: "METHODS FOR SCREENING FOR TRANSDOMINANT INTRACELLULAR EFFECTOR PEPTIDES AND RNA MOLECULES".

Because these errors were caused by the Patent Office, it is believed that no fee is necessary. However, if this belief is in error, the Commissioner is hereby authorized to charge any fee(s) which may be required, or credit any overpayment to Debit Account No. 06-1300 (Out Order No. A-64260-2/RMS/AMS).

Respectfully submitted,

FLEHR HOHBACH TEST ALBRITTON & HERBERT LLP

Anne M. Shyjan, Reg. No. 47,086, for Robin M. Silva, Reg. No. 38,304

Date: May 2, 2002

Flehr Hohbach Test Albritton & Herbert LLP Four Embarcadero Center, Suite 3400 San Francisco, CA 94111

1081575





# United States Patent and Trademary Offe

JUL 1 8 2007 COPY OF PAPERS ORIGINALLY FILED

> COMMISSIONER FOR PATENTS 160 UNITED STATES PATENT AND TRADEMARK OFFICE

WASHINGTON, D.C. 20231

www.uspto.gov APPLICATION NUMBER FILING DATE GRP ART UNIT FIL FEE REC'D ATTY.DOCKET.NO **DRAWINGS TOT CLAIMS** IND CLAIMS

08/963,368

11/03/1997

1627

460

A-64260-2/DJ

4

7

2

FLEHR

**FLENR** HOHBACH TEST ALBRITTON & HERBERT

**SUITE 3400** 

FOUR EMBARCADERO CENTER **SAN FRANCISCO, CA 941114187** 

**CONFIRMATION NO. 9991** CORRECTED FILING RECEIPT 

OC000000007821808\*

Date Mailed: 04/08/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s) GARRY -GERRY P. NOLAN, MENLO PARK, CA;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A DIV OF 08/789,333 01/23/1997 PAT 6,153,380 WHICH IS A DIV OF 08/787,738 01/23/1997 WHICH IS A CON OF 08/589,108 01/23/1996 ABN

AND A CIP OF 08/589,911 01/23/1996 ABN-

AND A CON OF 08/787.738 01/23/1997 WHICH ARE BOTH CIPS OF 08/589,109

Foreign Applications OF 08/589,109 01/23/96 AND 08/589,911 01/23/96

If Required, Foreign Filing License Granted 12/27/1997

Projected Publication Date: Not Applicable, filed prior to November 29,2000

Non-Publication Request: No

Early Publication Request: No

\*\* SMALL ENTITY \*\*

Title

TRANSDOMINANT

PEPTIDES

METHODS FOR SCREENING FOR TRANSDOMINAT INTRACELLULAR EFFECTOR PEPIDES-AND RNA MOLECULES

### Preliminary Class



## LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

#### GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).